{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-023381","form_type":"8-K/A","ticker":"PMI","cik":"0002030617","company_name":"Picard Medical, Inc.","filed_at":"2026-07-13T11:57:57+00:00","discovered_at":"2026-07-13T12:00:00.279570+00:00","generated_at":"2026-07-13T12:00:06.228374+00:00","sec_items":["9.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Picard Medical Q1 revenue up 85% YoY; gross margin improves to 24%","bullets":["Revenue for first three months of 2026 increased 85% YoY; U.S. revenue up 116%.","Gross margin improved to 24% from -4% in 2025.","Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.","Interim CEO Richard Fang acknowledges recent leadership changes but reaffirms mission.","Annual meeting set for July 17, 2026; proposals include director elections and capital structure amendments."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-023381","json":"https://secwatch.observer/filing/0001437749-26-023381.json","markdown":"https://secwatch.observer/filing/0001437749-26-023381.md","text":"https://secwatch.observer/filing/0001437749-26-023381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000143774926023381/0001437749-26-023381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000143774926023381/pmi20260710_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T12:00:06.228374+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}